comparemela.com
Home
Live Updates
Evaluated Against Pediatric Solid Tumors - Breaking News
Pages:
Latest Breaking News On - Evaluated against pediatric solid tumors - Page 1 : comparemela.com
SELLAS Life Sciences CDK9 Inhibitor GFH009 Selected for Pediatric Preclinical in Vivo Testing (PIVOT) Program in Pediatric Cancers by the National Cancer Institute
GFH009 to be Evaluated Against Pediatric Solid Tumors and Leukemia Models at Eight Participating Research Institutions.
United states
Angelos stergiou
National cancer institute
Jude children research hospital
Md anderson cancer center
Genfleet therapeutics shanghai inc
Life sciences group inc
Leukemia models at eight participating research institutions
Jackson laboratory
Memorial sloan kettering cancer center
Funded throughcooperative agreement grants
National cancer
Evaluated against pediatric solid tumors
Leukemia models
Eight participating research
Sciences group
vimarsana © 2020. All Rights Reserved.